Recent advances in basic and clinical research have enhanced our understanding of the underlying biological and genetic variations associated with myeloproliferative neoplasms. These advances have enhanced classification and diagnosis of disease, contributed to more robust risk stratification models and identified novel targeted therapies for the optimization of clinical outcomes and enhanced quality of life. However, clinical challenges involving diagnosis, assessment of prognosis and prediction of patient outcomes still remain. As we continue to develop our understanding of MPNs and the biological processes involved in myeloid proliferation, abnormal proliferation, and dysplasia, health care professionals must be kept current of these emerging, clinically relevant findings to provide optimal care to patients with MPNs enhancing quality of life and overall clinical outcomes.
In this presentation, Dr. Srdan Verstovsek discusses the survival benefit of JAK inhibition in myelofibrosis, and whether a JAK inhibitor should be used for all myelofibrosis patients.
Earn accreditation for this activity at the following location:
© 2014 Imedex, LLC.